Hidden risks of first-line regimen switching in antiretroviral therapy-treated patients
{{output}}
Background: Dolutegravir (DTG) became central to South Africa's (SA's) first-line human immunodeficiency virus (HIV) regimen since 2019, offering improved tolerability, fewer drug-drug interactions, and a higher resistance bar... ...
